Trial Profile
An open-label study of TAK-536 in hypertensive patients with renal disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary)
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 24 May 2016 New trial record